HLA-DRB1*0901-Restricted Proliferative Responses of bcr-abl b3a2-Specific CD4+ T-Cell Clones
Exp. 1-150 Clone . | APC . | MoAb Added . | Peptide Stimulation . | Proliferative Response (cpm) (mean ± SD) . |
---|---|---|---|---|
MY-1 | auto PBMC | None | None | 259 ± 37 |
b3a2 | 26,771 ± 2,628 | |||
b2a2 | 324 ± 28 | |||
b3b4 | 332 ± 31 | |||
1A-a2 | 300 ± 29 | |||
anti–HLA-DR | b3a2 | 449 ± 69 | ||
anti–HLA-DQ | b3a2 | 26,678 ± 3,326 | ||
anti–HLA-DP | b3a2 | 26,139 ± 4,559 | ||
TO-1 | auto PBMC | None | None | 219 ± 24 |
b3a2 | 31,309 ± 3,237 | |||
b2a2 | 279 ± 102 | |||
b3b4 | 145 ± 6 | |||
1A-a2 | 157 ± 11 | |||
anti–HLA-DR | b3a2 | 308 ± 200 | ||
anti–HLA-DQ | b3a2 | 25,664 ± 523 | ||
anti–HLA-DP | b3a2 | 29,731 ± 2,632 |
Exp. 1-150 Clone . | APC . | MoAb Added . | Peptide Stimulation . | Proliferative Response (cpm) (mean ± SD) . |
---|---|---|---|---|
MY-1 | auto PBMC | None | None | 259 ± 37 |
b3a2 | 26,771 ± 2,628 | |||
b2a2 | 324 ± 28 | |||
b3b4 | 332 ± 31 | |||
1A-a2 | 300 ± 29 | |||
anti–HLA-DR | b3a2 | 449 ± 69 | ||
anti–HLA-DQ | b3a2 | 26,678 ± 3,326 | ||
anti–HLA-DP | b3a2 | 26,139 ± 4,559 | ||
TO-1 | auto PBMC | None | None | 219 ± 24 |
b3a2 | 31,309 ± 3,237 | |||
b2a2 | 279 ± 102 | |||
b3b4 | 145 ± 6 | |||
1A-a2 | 157 ± 11 | |||
anti–HLA-DR | b3a2 | 308 ± 200 | ||
anti–HLA-DQ | b3a2 | 25,664 ± 523 | ||
anti–HLA-DP | b3a2 | 29,731 ± 2,632 |
Exp. 2-151 Clone . | APC . | Peptide Stimulation . | Proliferative Response (cpm) (mean ± SD) . |
---|---|---|---|
MY-1 | None | None | 210 ± 52 |
b3a2 | 870 ± 212 | ||
L-Neo | None | 214 ± 20 | |
b3a2 | 702 ± 145 | ||
L-DR9 | None | 248 ± 48 | |
b3a2 | 24,208 ± 507 | ||
L-DR4 | None | 254 ± 79 | |
b3a2 | 799 ± 97 | ||
TO-1 | None | None | 268 ± 30 |
b3a2 | 936 ± 62 | ||
L-Neo | None | 262 ± 34 | |
b3a2 | 893 ± 22 | ||
L-DR9 | None | 308 ± 50 | |
b3a2 | 29,760 ± 2,554 | ||
L-DR4 | None | 358 ± 27 | |
b3a2 | 723 ± 54 | ||
None | L-DR9 | None | 227 ± 25 |
b3a2 | 367 ± 188 |
Exp. 2-151 Clone . | APC . | Peptide Stimulation . | Proliferative Response (cpm) (mean ± SD) . |
---|---|---|---|
MY-1 | None | None | 210 ± 52 |
b3a2 | 870 ± 212 | ||
L-Neo | None | 214 ± 20 | |
b3a2 | 702 ± 145 | ||
L-DR9 | None | 248 ± 48 | |
b3a2 | 24,208 ± 507 | ||
L-DR4 | None | 254 ± 79 | |
b3a2 | 799 ± 97 | ||
TO-1 | None | None | 268 ± 30 |
b3a2 | 936 ± 62 | ||
L-Neo | None | 262 ± 34 | |
b3a2 | 893 ± 22 | ||
L-DR9 | None | 308 ± 50 | |
b3a2 | 29,760 ± 2,554 | ||
L-DR4 | None | 358 ± 27 | |
b3a2 | 723 ± 54 | ||
None | L-DR9 | None | 227 ± 25 |
b3a2 | 367 ± 188 |
Abbreviation: Exp., experiment.
Incorporation of 3H-TdR into cloned T cells was determined in the presence of autologous APCs with and without various types of synthetic peptide and with and without anti-HLA MoAb.
Incorporation of 3H-TdR into cloned T cells was determined in the presence and absence of various types of APC with and without b3a2 peptide.